Business
Cytokinetics Announces Four Presentations at the 32nd International Symposium on ALS/MND
SOUTH SAN FRANCISCO, Calif., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced one oral presentation and three
About this update from Cytokinetics, Incorporated
[{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced one oral presentation and three poster presentations at the 32nd International Symposium on ALS/MND taking place online from December 7 – December 10, 2021. Oral Presentation Session Title: Session 5: Autonomy and Decision MakingPresentation Title: IMPACT ALS Europe – a European Survey of People Living with ALSPresenter: Mark Heverin, Research Manager, Academic Unit of Neurology, Trinity College Dublin Presentation Number: C14Date: December 8, 2021Session Time: 4:50 – 6:00 PM GMTPresentation Time: 5:30 – 5:45 PM GMT Poster Presentations Session Title: Live Poster Session ATheme: 09 – Clinical Trials and Trial DesignPresentation Title: Relationship Between Quantitative Strength Changes and Functional Outcomes in the Phase 2 FORTITUDE-ALS TrialPresenter: Bill Jacobsen, M.D., Neurologist, Gregory W. Fulton ALS and Neuromuscular Disease Center and Assistant Professor, Department of Neurology at the Barrow Neurological Institute Poster Number: CLT-10Date: December 7, 2021Session Time: 4:50 – 6:20 PM GMT Session Title: Live Poster Session ATheme: 09 – Clinical Trials and Trial DesignPresentation Title: Update of COURAGE-ALS: A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Study to Evaluate Efficacy and Safety of Reldesemtiv in Patients with ALSPresenter: Stacy Rudnicki, M.D., Vice President, Clinical Research, Cytokinetics Poster Number: CLT-15Date: December 7, 2021Session Time: 4:50 – 6:20 PM GMT Session Title: Live Poster Session CTheme: 09 – Clinical Trials and Trial DesignPresentation Title: Grip Strength is More than a Number: The Relationship Between Grip Strength and Fine Motor and Arm Function in FORTITUDE-ALSPresenter: Andrew Wolff, M.D., Senior Vice President, Senior Fellow, Clinical Research and Development, CytokineticsPoster Number: CLT-36Date: December 9, 2021Session Time: 4:50 – 6:20 PM GMT About Cytokinetics Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug ...